Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lentinan nasal drops for mild to moderate COVID-19 Omicron upper respiratory infection
ChiCTR2300070776Phase 4Recruiting
- Sponsor
- Changhai Hospital
- Start
- Jun 2022
- Modality
- Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lentinan in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Changhai Hospital. Primary endpoint: Virus negative rate at Day 10. Started Jun 2022; status: recruiting.
02
Drugs
lentinan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300070776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070776.